Parabilis Medicines Secures $305 Million Series F to Advance First-in-Class β-Catenin Inhibitor Zolucatetide
核心洞察
Parabilis Medicines (搜索) closed an oversubscribed $305 million Series F financing co-led by RA Capital Management (搜索), Fidelity Management & Research Company (搜索), and Janus Henderson Investors (搜索).
The funding will support continued clinical development of zolucatetide (搜索) (FOG-001), the first direct inhibitor of the β-catenin (搜索):TCF (搜索) interaction, toward a registrational trial in desmoid tumors.
Early Phase 1/2 data demonstrated meaningful single-agent activity across five Wnt/β-catenin (搜索)-driven tumor types, including desmoid tumors which received FDA Fast Track Designation.
Parabilis Medicines (搜索) announced the successful closing of a $305 million Series F financing round, marking one of the largest biotech fundraising efforts in recent months. The oversubscribed round was co-led by RA Capital Management (搜索), Fidelity Management & Research Company (搜索), and Janus Henderson Investors (搜索), with participation from new investors including Frazier Life Sciences, Soleus Capital, and a life science-dedicated investment fund.
The Cambridge-based clinical-stage biopharmaceutical company will use the proceeds to advance its lead investigational therapy, zolucatetide (搜索) (FOG-001), toward a registrational trial in desmoid tumors while continuing evaluation across multiple tumor types. The financing was completed at an increased valuation relative to the company's prior financing.
Breakthrough in Targeting "Undruggable" Proteins
Zolucatetide (搜索) represents a significant scientific achievement as the first and only direct inhibitor of the elusive β-catenin (搜索):TCF (搜索) interaction, a key downstream node within the Wnt/β-catenin pathway. This pathway is implicated in millions of cancer cases annually yet remains unaddressed by any approved therapies, highlighting the substantial unmet medical need.
"Our goal at Parabilis is to develop medicines with the potential to deliver truly life-changing impact for patients who urgently need new treatment options," said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines (搜索). "We are deeply grateful for the support and confidence of our world-class investors, which will enable us to advance zolucatetide (搜索) across a range of rare and common tumor types – creating the opportunity for a pipeline within a product."
Promising Clinical Data Across Multiple Tumor Types
The financing follows compelling preliminary data from Parabilis's ongoing Phase 1/2 trial of zolucatetide (搜索) presented in the fourth quarter of 2025. Early results demonstrated meaningful single-agent activity across five low complexity tumor types driven by Wnt/β-catenin (搜索) alterations, including desmoid tumors and adamantinomatous craniopharyngioma (ACP).
Notably, desmoid tumors have been granted Fast Track Designation from the U.S. Food & Drug Administration, expediting the regulatory pathway for this rare indication. The findings also showed strong scientific rationale for combination approaches in more biologically complex cancers, including microsatellite-stable colorectal cancer (MSS CRC).
At the upcoming J.P. Morgan Healthcare Conference, Parabilis plans to share additional data in desmoid tumors, as well as early clinical evidence of zolucatetide (搜索)'s potential in hepatocellular carcinoma (HCC) and familial adenomatous polyposis (FAP). The company has committed to providing additional data readouts throughout 2026.
Expanding Pipeline Through Helicon Platform
Beyond zolucatetide (搜索), Parabilis continues to demonstrate the broad applicability of its proprietary Helicon platform. The company has generated encouraging preclinical data from its Helicon degrader programs targeting ERG (搜索) and allosteric ARON (搜索), two historically intractable targets in prostate cancer. These programs highlight the platform's ability to repeatedly generate multiple differentiated therapeutic candidates against high-value targets.
"Successfully drugging a target long considered undruggable requires both deep biological insight and a differentiated technological approach. With Helicons, Parabilis has established a platform with the potential to generate a robust pipeline of impactful therapies," said Jake Simson, Ph.D., Partner at RA Capital.
Addressing the "Undruggable" Proteome
Despite decades of progress in drug development, the vast majority of the human proteome remains "undruggable" with today's modalities. Many key disease drivers are intracellular—out of reach for antibodies—and have only flat protein surfaces that small molecules can't effectively bind. Parabilis's α-helical Helicon peptides, designed based on the pioneering work of Greg Verdine, are engineered to overcome these limitations, creating a new path to selectively engage disease-driving targets long considered out of reach.
The company leverages over a decade of proprietary data, laboratory innovations, and AI- and physics-based algorithms to develop this new class of stabilized, cell-penetrant alpha-helical peptides capable of modulating intracellular proteins that are inaccessible to traditional drug modalities.